1. Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255-323.
2. Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Research and Clinical Practice. 2019;157:107843.
3. Rostoski O. Über die Zunahme der Zuckerkranken Munch Med Wochenschr 100(9):342-346. 1958.
4. Schliack V. Die Verbreitung des Diabetes mellitus: Häufigkeit und Vorkommen in Europa und Amerika. In: Pfeiffer E, editor. Handbuch des Diabetes mellitus Pathophysiologie und Klinik München: J.F. Lehmanns Verlag 1968. p. 333-64.
5. Heidemann C, Du Y, Paprott R, Haftenberger M, Rathmann W, Scheidt-Nave C. Temporal changes in the prevalence of diagnosed diabetes, undiagnosed diabetes and prediabetes: findings from the German Health Interview and Examination Surveys in 1997–1999 and 2008–2011. Diabetic Medicine. 2016;33(10):1406-14.
6. Buchmann N, Fink A, Tegeler C, Demuth I, Doblhammer G, Steinhagen-Thiessen E. Different treatment forms of type II diabetes and the risk of dementia in German health claims data. Acta Diabetologica. 2019;56(9):995-1003.
7. Xu WL, Von Strauss E, Qiu CX, Winblad B, Fratiglioni L. Uncontrolled diabetes increases the risk of Alzheimer’s disease: a population-based cohort study. Diabetologia. 2009;52(6):1031-9.
8. Harris MI, Eastman RC. Early detection of undiagnosed diabetes mellitus: a US perspective. Diabetes Metab Res Rev. 2000;16(4):230-6.
9. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes. New England Journal of Medicine. 2008;359(15):1577-89.
10. Stratton IM. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405-12.
11. Young BA, Lin E, Korff MV, Simon G, Ciechanowski P, Ludman EJ, et al. Diabetes Complications Severity Index and Risk of Mortality, Hospitalization, and Healthcare Utilization. 2008;14(1):10.
12. Chen H-L, Hsiao F-Y. Risk of hospitalization and healthcare cost associated with Diabetes Complication Severity Index in Taiwan's National Health Insurance Research Database. Journal of Diabetes and Its Complications. 2014;28(5):612-6.
13. Hazel-Fernandez L, Li Y, Nero D, Moretz C, Slabaugh L, Meah Y, et al. Relationship of diabetes complications severity to healthcare utilization and costs among Medicare Advantage beneficiaries. Am J Manag Care. 2015;21(1):e62-70.
14. Pantalone KM, Misra-Hebert AD, Hobbs TM, Ji X, Kong SX, Milinovich A, et al. Antidiabetic treatment patterns and specialty care utilization among patients with type 2 diabetes and cardiovascular disease. Cardiovascular Diabetology. 2018;17(1).
15. Weng W, Liang Y, Kimball E, Hobbs T, Kong S. Trends in comorbidity burden and treatment patterns in type 2 diabetes: Longitudinal data from a US cohort from 2006 to 2014. Diabetes Res Clin Pract. 2018;142:345-52.
16. Hu WS, Lin CL. Use of the progression of adapted Diabetes Complications Severity Index to predict acute coronary syndrome, ischemic stroke, and mortality in Asian patients with type 2 diabetes mellitus: A nationwide cohort investigation. Clinical Cardiology. 2018;41(8):1038-43.
17. Hu W-S, Hsieh M-H, Lin C-L. Comparisons of changes in the adapted diabetes complications severity index and CHA2DS2-VASc score for atrial fibrillation risk stratification in patients with type 2 diabetes mellitus: A nationwide cohort study. International Journal of Cardiology. 2018;269:122-5.
18. Bertram L, Böckenhoff A, Demuth I, Düzel S, Eckardt R, Li SC, et al. Cohort profile: The Berlin Aging Study II (BASE-II). Int J Epidemiol. 2014;43(3):703-12.
19. Demuth I, Banszerus V, Drewelies J, Duezel S, Seeland U, Spira D, et al. Cohort Profile Update: GendAge and Berlin Aging Study II (BASE-II). medRxiv. 2020:2020.09.05.20187898.
20. American Diabetes A. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2019. Diabetes Care. 2019;42(Suppl 1):S13-S28.
21. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-83.
22. Meyer A, Salewsky B, Spira D, Steinhagen-Thiessen E, Norman K, Demuth I. Leukocyte telomere length is related to appendicular lean mass: cross-sectional data from the Berlin Aging Study II (BASE-II). The American Journal of Clinical Nutrition. 2016;103(1):178-83.
23. Heidemann C S-NC. Journal of Health Monitoring | 3/2017 | Prävalenz, Inzidenz und Mortälität von Diabetes mellitus. 1960.
24. Kautzky-Willer A, Harreiter J, Pacini G. Sex and Gender Differences in Risk, Pathophysiology and Complications of Type 2 Diabetes Mellitus. Endocrine Reviews. 2016;37(3):278-316.
25. Martin S, Schramm W, Schneider B, Neeser K, Weber C, Lodwig V, et al. Epidemiology of Complications and Total Treatment Costs from Diagnosis of Type 2 Diabetes in Germany (ROSSO 4). Experimental and Clinical Endocrinology & Diabetes. 2007;115(08):495-501.
26. Williams JW, Zimmet PZ, Shaw JE, De Courten MP, Cameron AJ, Chitson P, et al. Gender differences in the prevalence of impaired fasting glycaemia and impaired glucose tolerance in Mauritius. Does sex matter? Diabetic Medicine. 2003;20(11):915-20.
27. Nauck M, Gerdes C, Petersmann A, Müller-Wieland D, Müller UA, Freckmann G, et al. Definition, Klassifikation und Diagnostik des Diabetes mellitus: Update 2020. Der Diabetologe. 2021;17(4):404-10.
28. Raparelli V, Elharram M, Moura CS, Abrahamowicz M, Bernatsky S, Behlouli H, et al. Sex Differences in Cardiovascular Effectiveness of Newer Glucose‐Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus. Journal of the American Heart Association. 2020;9(1).
29. Karagiannis T, Tsapas A, Athanasiadou E, Avgerinos I, Liakos A, Matthews DR, et al. GLP-1 receptor agonists and SGLT2 inhibitors for older people with type 2 diabetes: A systematic review and meta-analysis. Diabetes Res Clin Pract. 2021;174:108737.
30. Rathmann W, Haastert B, Icks A, Löwel H, Meisinger C, Holle R, et al. High prevalence of undiagnosed diabetes mellitus in Southern Germany: Target populations for efficient screening. The KORA survey 2000. Diabetologia. 2003;46(2):182-9.